Ironwood Pharma

Ironwood Pharmaceuticals, Inc. is a healthcare company, which focuses on the development and commercialization of Gastrointestinal (GI) product opportunities in areas of significant unmet need, leveraging demonstrated expertise and capabilities in GI diseases. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ironwood Pharma excels in Q4 with LINZESS growth and pipeline advancements

Ironwood Pharmaceuticals delivered a strong performance in Q4 2022, driven by LINZESS's growth and pipeline progress. Strategic priorities emphasize profitability and portfolio strength, while challenges around pricing and data release plans require attention. Opportunities exist in expanding LINZESS sales, pediatric indications, and pipeline investments for future growth.

Ironwood Pharma excels in Q1 with LINZESS driving growth

Ironwood Pharma's Q1 2023 showcased strong LINZESS demand, revenue growth, and profitability. The company's strategic focus on LINZESS and innovative pipeline positions it well for sustained success amidst market challenges and growth opportunities.

Ironwood Pharma reports strong Q2 performance and growth opportunities

Ironwood Pharmaceuticals showcased strong performance in Q2 2023, driven by robust U.S. net sales and strategic acquisitions.
While facing challenges in managing the impact of the VectivBio acquisition on EBITDA, the company is well-positioned for growth.
Opportunities lie in expanding LINZESS sales, advancing pipeline candidates like apraglutide, and diversifying into new indications.
Overall, Ironwood's focus on maximizing key products, pipeline advancement, and financial management sets a positive trajectory.

Ironwood Pharma reports strong Q3 performance amidst strategic acquisitions

Ironwood Pharmaceuticals showcased strong performance driven by LINZESS and the acquisition of VectivBio for apraglutide.
While facing challenges in managing financial losses and addressing competitive pressures, Ironwood remains focused on growth opportunities and product development.
Opportunities lie in upcoming Phase III data for apraglutide, pediatric market expansion for LINZESS, and exploring new patient subgroups for apraglutide.

Ironwood Pharma excels in Q4, eyes pediatric market growth

Ironwood Pharmaceuticals showcased robust financial performance, strategic acquisitions, and a focus on pipeline assets during their Q4 2023 earnings call. While facing challenges in defining efficacy and pricing strategies, the company remains optimistic about growth opportunities in the GI market, particularly in the pediatric segment.

Ironwood Pharma reports Q1 growth, prepares for apraglutide launch

Ironwood Pharma's Q1 2024 performance reflects growth in LINZESS prescription volume and positive developments in its pipeline, despite challenges in net sales and guidance adjustments. The company's strategic focus on maximizing LINZESS and preparing for apraglutide's launch presents opportunities for future growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Participants Jason Butler - JMP Securities David Amsellem - Piper Sandler Boris Peaker - TD Cowen Tim Chiang - Capital One Operator Thank you for standing by. My name is Aaron, and I will be your conference operator for today.

Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Call Transcript

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2023 results and recent business performance. “We are proud of the progress we have made across our strategic priorities so far this year, as we believe we have strengthened our position to become the leading GI healthcare company in the industry,” said Tom McCourt, chief executive officer of Ironwood. “Our high conviction in the STARS clinical program was au.

Ironwood Pharmaceuticals Reports Third Quarter 2023 Results

Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently acquired VectivBio and its drug candidate apraglutide, which is undergoing evaluation for the treatment of short bowel syndrome with intestinal failure.

Ironwood Pharmaceuticals: The Right Play Now

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its third quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 9, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood's website at www.ir.

Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented new data from four scientific abstracts during the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting and Postgraduate Course. These data provide further insight into the impact of linaclotide on symptoms of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), as well as the burden of these disorders on patients.

Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented positive final data from the company's Phase II STARS Nutrition program during United European Gastroenterology (UEG) Week. This multicenter study of nine patients was designed to evaluate the safety, pharmacokinetics, and efficacy of apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog, on intestinal absorption in adult patients who have Short.

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) Annual Meeting demonstrating that linaclotide decreased the use of rescue medications in children and adolescents ages 6-17 years-old with functional constipation. These findings build on previously announced data from the company's pivotal P.

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Why Is Ironwood (IRWD) Down 9.6% Since Last Earnings Report?

Ironwood Pharmaceuticals specializes in the development and commercialization of drugs for gastrointestinal diseases, with a focus on conditions like irritable bowel syndrome and chronic constipation. The company has demonstrated growth in total revenues, primarily driven by sales of its drug LINZESS in the US. Ironwood's product portfolio includes approved drugs as well as pipeline candidates targeting various gastrointestinal disorders, offering growth potential and diversification.

Ironwood: Pipeline Progresses As FDA Approves LINZESS

Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.

Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.21 per share a year ago.

Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Surpass Estimates

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its second quarter 2023 results and updated its full year 2023 financial guidance. “We made significant progress towards the goal of becoming the leading GI healthcare company, as the second quarter was truly transformative for Ironwood,” said Tom McCourt, chief executive officer of Ironwood. “LINZESS continued its strong momentum with another quarter of impressive performance.

Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, August 8, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) or (240) 789-2701 (international) using conference ID number and event passcode 4671230. To access the webcast, please visit the Investors section of Ironwood's website at www.iron.

Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call

Cogint

California Resources

Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

VectivBio Holding AG

BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion of the tender offer to purchase the outstanding ordinary shares of VectivBio (the “Shares”) for $17.00 per share in cash (.

Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares

BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Ironwood's pending ac.

Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio

Ironwood (IRWD) lead drug Linzess gets FDA approval for pediatric functional constipation The label expansion of the drug is expected to boost the company's sales.

Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved LINZESS® (linaclotide) as a once-daily treatment for pediatric patients ages 6-17 years-old with functional constipation. LINZESS is the first and only FDA-approved prescription therapy for functional constipation in this patient population. Earlier this year, the FDA granted a 6-month priority review to our supple.

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

Ironwood's drug Linzess is seeing its sales start to plateau. It could get an expanded indication for Linzess that delays a decline in revenue.

Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of VectivBio Holding AG (NasdaqGS: VECT) to Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD). Under the terms of the proposed transaction, shareholders of VectivBio will receive $17.00 in cash for each share of VectivBio that they own. KSF is seeking to determine whether this consideration and the process that led.

VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT

Ironwood (IRWD) offers to acquire VectivBio, which will help strengthen its gastrointestinal treatment portfolio.

Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6%

Investors cheered the gastrointestinal treatment specialist's latest asset buy. This, despite the fact that it's paying a more-than 40% premium, according to the terms of the deal.

Why Ironwood Pharmaceuticals Stock Bumped Higher Today

Ironwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock skidded.

VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion

Ironwood Pharmaceuticals is paying $17 a share for the Swiss biotech company.

News for Ironwood Pharma Stock (IRWD)